JP2007513634A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513634A5
JP2007513634A5 JP2006544104A JP2006544104A JP2007513634A5 JP 2007513634 A5 JP2007513634 A5 JP 2007513634A5 JP 2006544104 A JP2006544104 A JP 2006544104A JP 2006544104 A JP2006544104 A JP 2006544104A JP 2007513634 A5 JP2007513634 A5 JP 2007513634A5
Authority
JP
Japan
Prior art keywords
hbc
sequence
residues
residue
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006544104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513634A (ja
Filing date
Publication date
Priority claimed from US10/732,862 external-priority patent/US20040146524A1/en
Priority claimed from US10/787,734 external-priority patent/US7361352B2/en
Application filed filed Critical
Publication of JP2007513634A publication Critical patent/JP2007513634A/ja
Publication of JP2007513634A5 publication Critical patent/JP2007513634A5/ja
Pending legal-status Critical Current

Links

JP2006544104A 2003-12-10 2004-12-09 インフルエンザ免疫原及びワクチン Pending JP2007513634A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/732,862 US20040146524A1 (en) 2002-02-21 2003-12-10 Stabilized immunogenic HBc chimer particles
US10/787,734 US7361352B2 (en) 2001-08-15 2004-02-26 Influenza immunogen and vaccine
PCT/US2004/041879 WO2005055957A2 (en) 2003-12-10 2004-12-09 Influenza immunogen and vaccine

Publications (2)

Publication Number Publication Date
JP2007513634A JP2007513634A (ja) 2007-05-31
JP2007513634A5 true JP2007513634A5 (enExample) 2008-02-07

Family

ID=34681746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544104A Pending JP2007513634A (ja) 2003-12-10 2004-12-09 インフルエンザ免疫原及びワクチン

Country Status (11)

Country Link
US (2) US7361352B2 (enExample)
EP (2) EP1708748A4 (enExample)
JP (1) JP2007513634A (enExample)
KR (1) KR101209484B1 (enExample)
CN (1) CN1913920B (enExample)
AU (1) AU2004296886B2 (enExample)
BR (1) BRPI0417509A (enExample)
CA (1) CA2549104A1 (enExample)
IL (1) IL200341A (enExample)
NO (1) NO20063157L (enExample)
WO (1) WO2005055957A2 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CN1838967B (zh) * 2002-12-10 2010-05-26 洛伦蒂斯有限公司 稳定的免疫原性HBc嵌合体颗粒
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
CA2602456A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
CN104474543A (zh) 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310246B2 (en) * 2005-11-04 2010-12-23 Seqirus UK Limited Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
PT3320919T (pt) 2005-12-29 2020-09-03 Boehringer Ingelheim Animal Health Usa Inc Composições imunogénicas de pcv2 multivalentes e métodos para produzir composições deste tipo
AR058871A1 (es) 2005-12-29 2008-02-27 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos
EP3011969A1 (en) 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126887A2 (en) * 2006-03-27 2007-11-08 The Government Of The United States Of America Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
WO2007127290A2 (en) * 2006-04-24 2007-11-08 Protelix, Inc. Method for producing viral vaccine and therapeutic peptide antigens
CA2659592C (en) * 2006-07-14 2016-10-04 Konstantin V. Pugachev Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
BRPI0716536A2 (pt) * 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
EP2066343B1 (en) 2006-09-29 2017-06-14 Sanofi Pasteur Biologics, LLC Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
WO2008100290A2 (en) 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
EP2535058A3 (en) 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP2094872B2 (en) 2006-12-15 2020-02-19 Boehringer Ingelheim Animal Health USA Inc. Treatment of anti-PCV2 antibody seropositive pigs with PCV2 antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
CA2689296C (en) 2007-01-10 2015-11-17 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
WO2008100464A1 (en) * 2007-02-09 2008-08-21 Sanofi Pasteur Biologics Co. Viral vectors and methods of use
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CA2682047A1 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for increasing immunogenicity of glycoprotein vaccines
EP2185698B1 (en) * 2007-08-07 2015-04-22 Purdue Research Foundation Kinase inhibitors and uses thereof
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
CN101835487A (zh) * 2007-08-21 2010-09-15 戴纳瓦克斯技术公司 制备和使用流感蛋白质的组合物和方法
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2195466B1 (en) 2007-10-01 2012-10-10 Longhorn Vaccines & Diagnostics, LLC Method of storing biological specimens
US20100330190A1 (en) * 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
EP2231182A4 (en) * 2007-12-31 2012-08-22 Boehringer Ingelheim Vetmed PCV2 ORF2 VIRUS TYPE WITH FOREIGN AMINO ACID INSERTION
AU2009234345B2 (en) * 2008-01-23 2013-08-22 Boehringer Ingelheim Vetmedica, Inc. PCV2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
EP2240199A4 (en) * 2008-02-09 2012-10-03 Sanofi Pasteur Biologics Llc INFLUENZA VACCINES
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
AU2009314091B2 (en) * 2008-11-12 2015-05-14 Theraclone Sciences, Inc. Human M2e peptide immunogens
CN102316731B (zh) * 2008-12-10 2016-06-01 普渡研究基金会 基于细胞渗透性肽的激酶抑制剂
EP2391383B1 (en) 2009-02-02 2015-12-23 ChronTech Pharma AB Codon-optimized hepatitis b virus core antigen (hbcag)
ES2608841T3 (es) 2009-02-10 2017-04-17 Seqirus UK Limited Vacunas contra la gripe con cantidades reducidas de escualeno
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN103118709A (zh) * 2010-03-26 2013-05-22 新兴产品开发盖瑟斯堡有限公司 流感病毒基质2蛋白的胞外域、其表达系统和应用
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2012149045A2 (en) * 2011-04-26 2012-11-01 Molecular Express, Inc. Liposomal formulations
CN103083656A (zh) * 2011-10-27 2013-05-08 苏州科贝生物技术有限公司 甲型流感病毒保守肽M2e与病毒样颗粒的缀合物及应用
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2013111012A2 (en) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP3789002A1 (en) * 2012-09-05 2021-03-10 Stryker Corporation Patient support
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
US20150274784A1 (en) * 2012-11-07 2015-10-01 Vacplanta Limted Production of an Immunogen Using a Plant Virus
CA2924228C (en) 2013-10-02 2024-01-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
GB201421692D0 (en) * 2014-12-05 2015-01-21 Iquar Ltd Vaccines based on hepatitis B core antigens
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
IL280584B2 (en) 2018-08-02 2025-06-01 Univ Texas Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease
US20220356538A1 (en) * 2019-09-24 2022-11-10 The Penn State Research Foundation Hepatitis b virus mutants with increased covalently closed circular dna
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
US11975106B2 (en) 2020-03-26 2024-05-07 Provectus Pharmatech, Inc. Uses of halogenated xanthenes in oncology and virology
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원
CA3212672A1 (en) * 2021-03-04 2022-09-09 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) * 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4976958A (en) * 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
DE68929405T2 (de) * 1988-09-06 2003-02-06 Washington University, St. Louis Orale-immunisierung durch verwendung von transgenen pflanzen
US5023179A (en) * 1988-11-14 1991-06-11 Eric Lam Promoter enhancer element for gene expression in plant roots
US5110732A (en) * 1989-03-14 1992-05-05 The Rockefeller University Selective gene expression in plants
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5618988A (en) * 1990-03-02 1997-04-08 Amoco Corporation Enhanced carotenoid accumulation in storage organs of genetically engineered plants
JP3782442B2 (ja) * 1990-03-02 2006-06-07 ビーピー・コーポレーション・ノース・アメリカ・インコーポレーテッド 遺伝子操作した宿主におけるカロテノイドの生合成
US5057588A (en) 1990-03-09 1991-10-15 Hoechst Celanese Corp. Vinylidene cyanide alternating copolymers
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
US5297441A (en) * 1992-08-14 1994-03-29 The Boeing Company Apparatus for supporting a test specimen for compression testing
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JP3701761B2 (ja) * 1997-01-08 2005-10-05 本田技研工業株式会社 車両用シート
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
BR9809149A (pt) * 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
JP5132851B2 (ja) 1997-08-05 2013-01-30 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
ES2175668T3 (es) * 1997-12-16 2002-11-16 Chiron Corp Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
CA2320488C (en) * 1998-02-12 2007-03-06 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US5990085A (en) * 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
CN1306438A (zh) 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
HU229222B1 (en) 1998-12-04 2013-09-30 Biogen Idec Ma Inc Cambridge Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
EP1218514B1 (en) 1999-10-08 2006-04-26 Celltech Pharma Europe Limited Designing immunogens
US6737272B2 (en) 1999-12-10 2004-05-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulation of oocyte activation
ATE320493T1 (de) 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20030198645A1 (en) * 2002-02-21 2003-10-23 Mark Page Stabilized HBc chimer particles as therapeutic vaccine for chronic hepatitis

Similar Documents

Publication Publication Date Title
JP2007513634A5 (enExample)
JP2025004002A5 (enExample)
JP2005120106A5 (enExample)
JP2012095652A5 (enExample)
JP2020500015A5 (enExample)
JP2013501038A5 (enExample)
JP2009540801A5 (enExample)
JP2018138049A5 (enExample)
JP2018171063A5 (enExample)
JP2014506790A5 (enExample)
JP2013531477A5 (enExample)
JP2011087580A5 (enExample)
JP2014239686A5 (enExample)
JPWO2020072821A5 (enExample)
JP2002510494A5 (enExample)
JP2010068806A5 (enExample)
JP2022062113A5 (enExample)
JP2014507154A5 (enExample)
JP2013502226A5 (enExample)
JP2020517260A5 (enExample)
JP2008545393A5 (enExample)
JP2005509420A5 (enExample)
JP2010522568A5 (enExample)
JPWO2020014271A5 (enExample)
CA2509484A1 (en) Stabilized immunogenic hbc chimer particles